Table 1 Patient characteristics.
Parameter | Study cohort |
|---|---|
Cancer patients | n = 84 |
Gender [%]: | |
male-female | 64.2–35.7 |
Age [years, median and range] | 67.5 [38–87] |
BMI [kg/m2, median and range] | 24.1 [15.9–42.3] |
Tumor entity (prior / no prior therapy) [%] | |
NSCLC | 40.5 (41.7 / 37.5) |
Melanoma | 13.1 (8.3 / 25.0) |
Urogenital tract | 13.1 (11.7 / 16.7) |
GIT | 14.3 (16.7 / 8.3) |
Head and neck | 10.7 (15.0 / 0.0) |
Other malignancies | 8.3 (6.7 / 12.5) |
Staging [%] | |
UICC III | 6.2 |
UICC IV | 93.8 |
ECOG PS [%] | |
ECOG 0 | 7.1 |
ECOG 1 | 51.2 |
ECOG 2 | 39.3 |
ECOG 3 | 2.3 |
Therapeutic agent [%] | |
Nivolumab | 59.5 |
Pembrolizumab | 28.5 |
Nivolumab/Ipilimumab | 6.0 |
Other (Avelumab, Durvalumab) | 6.0 |
Smoker status [%] | |
Never | 9.5 |
Yes, ex | 39.2 |
Yes, present | 22.6 |
Unknown | 28.5 |
Prior lines of systemic therapy [%] | |
0 | 28.6 |
1 | 50.0 |
2 | 15.5 |
3 or more | 6.0 |
Side effects [%] | |
Any | 39.3 |
CTC G3 or higher | 11.9 |
PDL-1 score (prior / no prior therapy) [%] | |
≥50% | 21.5 (15.0/37.6) |
10–49% | 6.0 (6.7/4.2) |
1–10% | 8.4 (8.4/8.4) |
0% | 25.0 (31.7/8.3) |
unknown | 39.3 (38.3/41.7) |
